Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort

Creative Commons License

Raquel Palacios-Baena Z., Gutierrez-Gutierrez B., Calbo E., Almirante B., Viale P., Oliver A., ...More

CLINICAL INFECTIOUS DISEASES, vol.65, no.10, pp.1615-1623, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 65 Issue: 10
  • Publication Date: 2017
  • Doi Number: 10.1093/cid/cix606
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1615-1623
  • Hacettepe University Affiliated: Yes


Background. There is little information about the efficacy of active alternative drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems.